Protective effect of melatonin in a chronic experimental model of Parkinson's disease (Q44052474)

29 November 2017

title

Protective effect of melatonin in a chronic experimental model of Parkinson's disease (English)

1 reference

29 November 2017

0 references

1 reference

3

1 reference

29 November 2017

Federico Herrera

5

0 references

Juan C. Mayo

object named as

Juan Carlos Mayo

2

0 references

Carmen Rodriguez

object named as

Carmen Rodríguez

7

0 references

Vanesa Martín

6

object named as

Vanesa Martín

1 reference

29 November 2017

Isaac Antolín

1

1 reference

29 November 2017

María de los Angeles del Brío

4

1 reference

29 November 2017

language of work or name

English

0 references

publication date

1 July 2002

1 reference

29 November 2017

number of pages

11

1 reference

based on heuristic

inferred from page(s)

published in

Brain Research

1 reference

29 November 2017

volume

943

1 reference

29 November 2017

issue

2

1 reference

29 November 2017

page(s)

163-173

1 reference

Melatonin, mitochondria, and cellular bioenergetics

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902551-9

A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902551-9

Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902551-9

Evaluation of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated C57 black mouse model for parkinsonism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902551-9

Kinetics of nigral degeneration in a chronic model of MPTP-treated mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902551-9

A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902551-9

A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902551-9

Effects of melatonin on vertebrate circadian systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902551-9

Permeability of pure lipid bilayers to melatonin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902551-9

Plasticity of the nigrostriatal system in MPTP-treated mice. A biochemical and morphological correlation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902551-9

Melatonin protects against 6-OHDA-induced neurotoxicity in rats: a role for mitochondrial complex I activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902551-9

Chronic parkinsonism secondary to intravenous injection of meperidine analogues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902551-9

Melatonin and sleep in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902551-9

Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902551-9

Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on levels of glutathione in the extrapyramidal system of the mouse

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902551-9

Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902551-9

Neurochemical and histochemical characterization of neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on brain catecholamine neurones in the mouse.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902551-9

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902551-9

Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902551-9

MPTP produces differential oxidative stress and antioxidative responses in the nigrostriatal and mesolimbic dopaminergic pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902551-9

Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902551-9

Melatonin increases striatal dopaminergic function in 6-OHDA-lesioned rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902551-9

Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902551-9

When did Ray Kennedy's Parkinson's disease begin?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902551-9

Melatonin prevents apoptosis induced by 6-hydroxydopamine in neuronal cells: implications for Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902551-9

Nuclear localization of melatonin in different mammalian tissues: immunocytochemical and radioimmunoassay evidence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902551-9

Spontaneous regeneration of nigrostriatal dopaminergic neurons in MPTP-treated C57BL/6 mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902551-9

Apoptosis in neurodegenerative disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902551-9

Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902551-9

Fragile mitochondrial DNA: the missing link in the apoptotic neuronal cell death in Parkinson's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902551-9

Alpha-tocopherol in the ventricular cerebrospinal fluid of Parkinson's disease patients: dose-response study and correlations with plasma levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902551-9

Melatonin prevents death of neuroblastoma cells exposed to the Alzheimer amyloid peptide.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902551-9

Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902551-9

Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Parkinson Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902551-9

Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902551-9

Oxidative damage in the central nervous system: protection by melatonin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902551-9

A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902551-9

Astrocytic responses to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in cat and mouse brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902551-9

High melatonin solubility in aqueous medium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902551-9

Treatment of mice with methamphetamine produces cell loss in the substantia nigra.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902551-9

The pineal hormone melatonin inhibits DNA-adduct formation induced by the chemical carcinogen safrole in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902551-9

The nigrostriatal dopaminergic system as a preferential target of repeated exposures to combined paraquat and maneb: implications for Parkinson's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902551-9

Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902551-9

Melatonin prevents oxidative stress-induced cell death in hippocampal cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902551-9

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0006-8993(02)02551-9

1 reference

29 November 2017

1 reference